



Resonance Health Ltd
ASX / Media Release

27 August 2014

Resonance Health shortlisted for WA Innovator of the Year

We are delighted to advise that Resonance Health, in collaboration with The University of Western Australia, has been selected as a finalist in the Western Australia Innovator of the Year program for our HepaFat-Scan product: a non-invasive technology that enables magnetic resonance imaging scanners to measure the concentration of fat in the human liver.

The Innovator of the Year Program is about fostering a culture of innovation in WA and acknowledges the achievements of WA's leading innovation enterprises. Resonance Health is delighted to be shortlisted for this award, as a WA Company providing unique diagnostic imaging solutions for patients in Australia and internationally. All image analysis and reporting services are provided from our ISO 13485 certified facility in Perth and are utilised by hospitals in over 20 countries and in international clinical trials.

Our technologies are innovative, patent protected and address a large unmet need for non-invasive diagnostic tools for the diagnosis and monitoring of liver disease. HepaFat-Scan is our latest product to come to market and provides an accurate measurement of the concentration of fat in a patient's liver, addressing the growing prevalence of fatty liver disease in Australia and in many other countries. HepaFat-Scan has recently gained regulatory clearance to be marketed in the US, Australia and Europe.

The winner of the WA Innovator of the Year award will be announced on the 5th of November.

For further information please contact:

Resonance Health

Liza Dunne
Managing Director
T: +61 8 9286 5300
E: lizad@resonancehealth.com

Adrian Bowers
Company Secretary
T: +61 8 9286 5300
E: adrianb@resonancehealth.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing imaging core laboratory services for the quantitative analysis of MR medical images, with a subspecialty in the liver. Resonance Health's patented FerriScan technology provides a safe and accurate alternative for measuring liver iron concentration. HepaFat-Scan is FDA cleared for the measurement of liver fat and research continues into the development of new technology for the accurate assessment of liver fibrosis.